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ARTICLE
Clinical features and treatment with botulinum 
toxin in blepharospasm: a 17-year experience
Característica clínicas e tratamento com toxina botulínica em blefaroespasmo: 
experiência de 17 anos
Camila Catherine Aquino1, Andre C. Felício2, Pollyanna Celso Felipe de Castro1, Ricardo Araujo Oliveira1, 
Sonia Maria Cesar Azevedo Silva2, Vanderci Borges2, Henrique Ballalai Ferraz2
Blepharospam (BPS) is a focal dystonia characterized by in-
voluntary forceful eye closure and impaired opening of the eyes 
due to contractions involving the muscles orbicularis occuli, cor-
rugators, procerus and levator palpebrae1. BPS can occur isolated 
or in association with involuntary movements in lower face and 
neck, called as Meige syndrome, cranial dystonia, segmental cra-
niocervical dystonia or blepharospasm-plus2. Furthermore, BPS 
can also occur in the setting of neurodegenerative diseases, such 
as Parkinsonism, hereditary ataxias and generalized dystonias.
Among the focal dystonias, BPS and other cranial dys-
tonias usually have a late onset (~55 years-old)3 when 
compared with writer’s cramp, cervical dystonia and spas-
modic dysphonia4. There are few studies concerning the 
prevalence and incidence rates of this disorder in gener-
al population. The prevalence is estimated around 12–133 
cases per million5. According to a previous study conduct-
ed in Minnesota, USA, the annual occurrence of BPS is 1.2 
cases per 100.0006.
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ABSTRACT
Objective: It was to analyze clinical aspects of patients with blepharospasm, including outcomes of botulinum toxin treatment. Additionally, 
clinical characteristics of isolated blepharospasm were compared to those of blepharospasm plus other movement disorders. Methods: 
Clinical data recorded during 17 years were reviewed. The variables included age, gender, age of onset, past medical history, head trauma, 
smoking history, family history of dystonia, severity, duration of botulinum toxin relief and adverse effects. Results: A total of 125 patients 
were included and 75.2% were female. The mean age of onset was 54.3 years; 89.6% of the individuals started with contractions in eye region, 
and 39.2% of them spread to lower face or neck. Isolated blepharospasm group was compared with blepharospasm-plus group for demo-
graphic and clinical features, and therapeutic outcomes, without significant differences. Botulinum toxin treatment improved the severity of 
contractions (p=0.01) with low rate of side effects (14%). Conclusions: Both groups — isolated blepharospasm and blepharospasm-plus — 
shared similar results concerning epidemiology, clinical features and therapeutic response to botulinum toxin.
Key words: blepharospasm, botulinum toxins.
RESUMO
Objetivos: Analisar as características clínicas de pacientes com blefaroespasmo e os resultados do tratamento com toxina botulínica. Além 
disso, os pacientes foram divididos em dois grupos, blefaroespasmo isolado e blefaroespasmo associado a outros distúrbios do movimento, 
os quais foram comparados quanto a características clínicas e terapêuticas. Métodos: Foram revisados prontuários dos últimos 17 anos. As 
variáveis consideradas foram idade, sexo, idade de início dos sintomas, antecedentes pessoais, história prévia de trauma crânio-encefálico, 
tabagismo, história familiar de distonia, gravidade do blefaroespasmo, duração do efeito da toxina botulínica e efeitos adversos. Resultados: 
Foram incluídos 125 pacientes, dos quais 75,2% eram do sexo feminino. A média de idade do início dos sintomas era 54,3 anos; 89,6% dos 
pacientes tiveram início dos sintomas na região ocular e em 39,2% dos casos houve disseminação para face ou pescoço. Não houve diferen-
ças significativas entre os grupos blefaroespasmo isolado versus blefaroespasmo-plus. O tratamento com toxina botulínica proporcionou 
melhora dos sintomas (p=0,01) com baixa incidência de efeitos adversos (14%). Conclusões: Ambos os grupos — blefaroespasmo isolado 
e blefaroespasmo-plus — apresentaram as mesmas características clínicas, epidemiológicas e resposta terapêutica à toxina botulínica.
Palavras-Chave: blefaroespasmo, toxinas botulínicas.
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Patients with BPS are more likely to experience dysto-
nias in other parts of the body than patients with other fo-
cal dystonias7. Complaints of dry eye and photophobia are 
usually reported, but the exact nature of this association re-
mains unestablished5. Finally, concerning the genetic pat-
tern and inheritance of BPS, it seems that there is a higher 
frequency of focal dystonia in relatives, however with a con-
siderable phenotypic variability8.
The purpose of this study was to evaluate the demograph-
ic and clinical features, including outcomes of botulinum 
toxin treatment in patients with BPS referred to a Brazilian 
tertiary care center. Additionally, clinical characteristics of 
isolated blepharospasm were compared to those of blepha-
rospasm plus other movement disorder.
METHODS
Patients and data acquisition
This was a retrospective study, from 1993 to 2010, of 
125 consecutive patients with BPS seen at the Movement 
Disorder Unit of the Universidade Federal de São Paulo (São 
Paulo, Brazil). During those 17 years, clinical data were re-
corded in a systematic manner, using a standard clinical 
protocol. Each case, on the first consultation and subse-
quent follow-up, was evaluated by an unblinded movement 
disorder specialist. Incomplete or ambiguously recorded 
files were not included.
All patients had a detailed neurological examination to 
rule out other underlying neurological conditions. The criteria 
for diagnosis of BPS included observation of involuntary bilat-
eral increased blinking with intermittent dystonic eyelid and 
eyebrow contractions. Patients diagnosed with apraxia of eye-
lid opening were not included in this study. The severity of BPS 
was accessed according to the Jankovic rating scale9.
Clinical protocol
The primary aim of this study was to evaluate clinical fea-
tures and therapeutic outcomes of patients with BPS treat-
ed with botulinum toxin injections. Our secondary objective 
was to compare aforementioned variables between patients 
with and without associated movement disorders, particu-
larly oromandibular dyskinesia and other focal dystonias.
The following demographic data were recorded: gender, 
ethnicity (Caucasian, Asian and African Brazilians), age at 
last appointment and at symptom onset, disease duration, 
affected site at onset, associated movement disorder, trigger-
ing factors, family history of dystonia and previous history of 
head trauma. History of hypertension, alcohol intake or to-
bacco use were also recorded.
Informations regarding the oral and surgical treatment 
for blepharospasm were documented. Two different com-
mercial brands of botulinum toxin (BTX-A) were used 
throughout the study (Botox® and Dysport®), according to 
the product availability at the time of treatment. Standard 
doses of BTX-A were used on eye region whenever possible 
(Botox® 60UI and Dysport® 200UI). Additional sites were 
used if the previous sites had lead to side effects or less effec-
tiveness or the presence of associated movement disorders 
other than BPS. Treatment response was gauged based on 
the relief of symptoms between first and last injections.
All subjects signed the informed consent, which ex-
plained the treatment and also authorized publication of 
their data. This study was approved by the ethical committee 
of Universidade Federal de São Paulo (CEP number 1171/11).
Statistical analysis
Normality requirements for data distribution were con-
firmed using Kolmogorov-Smirnov test. Continuous data is 
presented as mean (±) standard deviation, and categorical 
data as absolute (n) or relative frequency (%). Comparisons 
between groups were carried out using Student’s t-test for 
continuous variables, whereas Pearson Chi-square test was 
used for contingency tables. Correlations between indepen-
dent variables were done using Pearson test. Linear regres-
sion analysis was also performed in order to adjust for con-
founding variables. A corrected p-value of 0.05 was set as the 
threshold for the statistical significance.
RESULTS
A total of 125 subjects were included in this statistical 
analysis. The epidemiological data and clinical features are 
presented in Table 1.
In relation to previous medical history, head trauma, in-
cluding mild, had occurred in 13 subjects (10.4%) before the 
onset of BPS. High blood pressure was present in 39.2% in-
dividuals, smoking in 20%, and heavy alcohol consumption 
in 8.8%. Glaucoma was present in only 4 (3.2%) patients. 
Diagnosis of previous psychiatric disease occurred in 8% of 
subjects, predominantly depression; 12 (9.6%) subjects re-
ported previous use of neuroleptic drug. Two patients were 
previously diagnosed with Myasthenia Gravis (MG), and the 
coexistence of both diseases (BPS and MG) is a valid possibil-
ity. Brain CT or MRI was conducted in 25 patients (20%), but 
no significant abnormality was found. Most patients present-
ed with mild periventricular abnormalities, characteristics of 
microangiopathy.
Before reporting to our center, 71 (56.8%) patients had 
taken oral medications for treatment of blepharospasm 
without significant improvement. The most frequently 
used drugs were: benzodiazepines (54.9%), anticholinergics 
(33.8%) and antidepressants (25.3%). In addition to clini-
cal treatment, ten patients had surgical treatment for BPS, 
such as blepharoplasty and myectomy.
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From a total of 125 subjects, 113 (90.4%) were treated with 
BTX-A. The severity of contractions in eyebrow and eyelid, 
before and after first BTX-A injection, is presented in Figure.
A total of 906 BTX-A injections were performed (mean 8/
patient; range=2–24 injections). The difference between se-
verity of BPS in both sites, before and after BTX-A injection 
was statistically significant, as shown in Figure. The mean 
duration of BTX-A effect after first injection was 3.1 months. 
After subsequent injections and adjustment of dosage and 
site, the duration of effect could be improved to 3.3 months 
(p=0.60). Side effects after treatment occurred in 14% of pa-
tients, and the most frequently reported were ptosis, blurred 
vision, diploplia and felling of “foreign body” in eyes.
The patients were further categorized into two groups — 
the ones with isolated BPS and the ones with BPS plus (BPS+) 
other movement disorders, such as oral dyskinesia, oroman-
dibular dystonia, spasmodic dysphonia and cervical dysto-
nia — in order to figure out if there were clinical differences 
between them. The comparison between BPS versus BPS+ 
groups is presented in Table 2. As showed, no statistically 
significant differences were found between patients in both 
groups, except for disease duration before being referred.
DISCUSSION
BPS is a primary adult-onset dystonia of unknown etiol-
ogy, but multiple environmental and genetic factors are likely 
implicated10. This study was undertaken to explore different 
clinical correlation of the disease, which could provide clues 
Table 1. Epidemiological data and clinical features of 125 subjects with blepharospasm.
Variables n (%) Mean (±SD)
Gender Female  94 (75.2)
Age at onset (y) 54.3 (±10.4)
Duration of symptoms before first 
evaluation (mo) 128.1 (±78.7)
Time of follow-up (mo) 72 (±48)
Ethnicity
Caucasian
African
Asian
85 (68)
8 (6.4)
9 (7.2)
Distribution of dystonia at onset
Eye
Oromandibular
Others (i.e.: cervical, vocal cords)
112 (89.6)
11 (8.8)
3 (2.4)
Movement disorder in follow-up
BPS isolated
BPS plus (Meige, craniocervical dystonia)
Other (parkinsonism, tremor)
65 (52)
49 (39.2)
8 (6.4)
Main triggering factors Stress, anxietyPhotophobia, light, clarity
34 (27.2)
13 (10.4)
Family history of dystonia 11 (8.8)
n: number of patients; y: years; mo: in months; SD: standard deviation.
Table 2. Comparison between blepharospams groups associated or not with other movement disorder.
Comparison of groups BPS(n=65)
BPS+
(n=57) p-value
Gender, female/male,ratio 2.82 (48/17) 3.2 (46/14) 0.13; NS
Ethnicity
Caucasian
African
Asian
49 (75.3%)
3 (4.16%)
2 (3.0%)
36 (63.15%)
5 (8.7%)
7 (12.2%)
0.17; NS
Age symptom onset (y) 54.1±11 54.0±10.3 0.90; NS
Disease duration before first visit (mo) 143±82.8 97±63 <0.01; S
Distribution of dystonia at onset
Eyes
Oral dyskinesia/dystonia
Larynx
Family history of dystonia
65 (100%)
2
52 (91.2%)
3 (5.2%)
1 (1.7%)
3 0.50; NS
Severity eyelid contractions before BTX-A* 3.19±0.97 3.08±0.93 0.90; NS
Severity eyelid contractions after first BTX-A* 1.51±1.23 0.96±0.91 0.13; NS
Duration of relief after first injection 3.37±3.75 2.82±1.28 0.69; NS
BPS: blepharospams groups; BPS+: blepharospams groups associated with other movement disorder; n: number of patients; y: years; mo: months; NS: without 
statistical significance; BTX-A: botulinum toxin. *See legend to Fig.
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as to the etiopathogenesis. The discussion that follows is di-
vided into two sets; firstly, we discuss BPS demographic and 
clinical features, and then its therapeutic outcomes compar-
ing to literature data.
Demographic and clinical features
Our patients presented the same average age, sex and eth-
nicity distribution as reported elsewhere11,12. The majority of pa-
tients had onset in the eye region, and almost 40% developed 
spread during the follow up. This is an interesting observation 
since the mean time of follow up was about six years, and some 
patients were followed during more than ten years. When asked 
about triggering factors, most patients reported stress and anx-
iety, followed by photophobia and light to be more relevant. 
Moreover, few subjects reported previous ocular disease, such 
as glaucoma. A recently published well designed study found an 
evidence of ocular disease such as dry eye, blepharitis and kera-
toconjuctivitis in 50 of 140 patients with BPS10.
Previous studies have showed non-significant associations 
between alcohol use, hypertension and minor head trauma 
(without loss of consciousness) with BPS13. On the other hand, 
head trauma with loss of consciousness13 and as a protective 
caffeine intake14, have been suggested as a risk factor and as 
a protective factor, respectively. The lack of a control group in 
our study precluded confirmation of those associations.
Concerning the family history of dystonia, we found a posi-
tive history reported by 8.8% of patients. We have to highlight 
that this data was acquired through patient report and that their 
family members were not examined in our center. Positive family 
history in previously published articles ranged from 7 to 32%, ac-
cording to distinct methodology and population studied8,12,13,15.
When patients with isolated BPS were compared with 
patients with BPS+, such as Meige syndrome, craniocervical 
dystonia and laryngeal dystonia, no significant differences 
were found, showing that those disorders are probably spec-
trum of the same disorder. In BPS+ group, BPS was the first 
presentation in 91.2% and subsequently spread to lower face, 
neck or vocal cords. BPS has the highest likelihood for further 
spread, occurring in about 33.3%, followed by dystonia of up-
per extremities, torticollis and laryngeal dystonia16.
Therapeutic outcomes
In our series, 113 out of 125 patients were treated with 
BTX-A. As showed in Figure, the severity of BPS improved ei-
ther in the eyebrow or eyelid. There were significant differ-
ences in BPS severity in each site before and after BTX. This 
response was evaluated in first injection, and, even thought 
we did not analyze the response in all subsequent injections, 
most of patients presented the same therapeutic effect dur-
ing follow up. According to a recent systematic review on 
botulinum toxin for BPS, although BTX is a highly safe treat-
ment for BPS, information about best regimen treatment, in-
jections techniques and formulations are not clear17.
In this study, we did not find significant differences with 
regard to the duration of symptom relief after BTX injection. 
The mean time of follow up was about 72 months, but some 
patients were seen throughout 10 years, and we did not find 
any case with secondary resistance to BTX-A.
In a previous Brazilian study, 30 patients with BPS under 
BTX-A treatment were evaluated and about 93% of them had 
symptom improvement, with maintenance of relief duration 
in the time of follow up and low incidence of side effect18. On 
Figure. Severity of blepharospasm before and after first botulinum toxin injection.
*Severity 0: no visible contraction. Severity 1: increased blinking present with external stimuli. Severity 2: mild but spontaneous fluttering, definitely noticeable, 
possibly embarrassing, but not functionally disabling. Severity 3: moderate, very noticeable spasm, mildly incapacitating. Severity 4: severe, incapacitating spasm.
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the other hand, a Canadian study on the duration of long-
term symptom relief in patients with either BPS or Hemifacial 
Spasm (HFS) found that the mean duration of relief in BPS 
patients after early injections was 13.5 weeks and after later 
injections was 11.4 weeks, with statistical significance. That 
difference was not found in HFS19.
Side effects occurred in 14% of patients in our sample, 
and most of them were mild and transient, agreeing with a 
systematic review that pointed to the safety of this thera-
peutic approach17.
Finally, we did not observe any differences in symptom re-
lief, duration or occurrence of side effects when we compared 
patients with isolated BPS and BPS plus other movement dis-
order, showing that they not only share the same clinical and 
demographic features but also therapeutic outcomes.
This study has several limitations, such as referral bias 
and its retrospective nature. Another problem was related to 
Brazil’s complex ethnic heterogeneity, hence it was difficult 
to separate patients clearly into subgroups according to eth-
nicity. Additionally, it is worth mentioning that this study was 
conducted in a community hospital, and, during the follow 
up, patients were treated with two different brands of BTX-A, 
as aforementioned. Because of that, we could not compare 
long term relief with distinct brands.
In this retrospective case-record study on a large 
population of BPS patients, we found that clinical and 
therapeutic outcomes in patients with BPS or BPS plus 
are similar. Accordingly, this Brazilian sample of patients 
taken together also has similar features as compared to 
literature data.
